Prestige Consumer Healthcare (PBH) Earnings Date & Reports

Key Takeaways

• Quarterly revenue rose 22.7% year over year to $336.3 million, lifted by the first full quarter of ownership of the Breathe Right and LaCorium acquisitions.
• Adjusted diluted earnings per share (EPS) climbed about 6% to $1.13, edging past consensus estimates near $1.07.
• Organic revenue, which excludes acquisitions and foreign currency, declined 1.6% on order timing and softer Clear Eyes sales.
• Reported (GAAP) diluted EPS fell to $0.53 from $0.86 a year ago, weighed down by acquisition-related costs and higher interest expense.
• Management lowered its fiscal 2027 outlook, citing renewed Clear Eyes production variability at the Pillar5 facility.
• For more on PBH's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are navigating current market conditions.

Earnings Context and Why It Matters

Prestige Consumer Healthcare operates on a fiscal year ending March 31, so its second quarter covered the July-to-September 2026 period. This report carried outsized importance for two reasons. First, it represented the first full quarter of ownership for the Breathe Right and LaCorium acquisitions, giving investors their clearest read yet on how those deals are translating into revenue and profit. Second, the quarter tested whether the company's core over-the-counter (OTC) healthcare portfolio could grow on its own, independent of deal-making. The recurring challenge of Clear Eyes supply disruptions at the Pillar5 production site has kept that eye-care brand in the spotlight, making this report a key gauge of both acquisition execution and operational recovery.

Reported Results

Prestige Consumer Healthcare reported second-quarter fiscal 2027 revenue of $336.3 million, up 22.7% from $274.1 million in the prior-year period. The Breathe Right and LaCorium acquisitions contributed $65.1 million to quarterly revenue, while organic revenue declined 1.6% versus the prior year, reflecting order timing pulled into the first quarter and weaker Clear Eyes sales.

Adjusted diluted EPS increased about 6% to $1.13, compared with $1.07 a year earlier and above consensus estimates near $1.07. On a reported basis under GAAP (Generally Accepted Accounting Principles), diluted EPS fell to $0.53 from $0.86, as the company absorbed inventory step-up amortization, Pillar5 remediation and idle-capacity costs, and a roughly threefold increase in interest expense tied to acquisition debt.

Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin reached approximately 33.6%, while adjusted gross margin improved to 57.7% from 55.3%. For the first half, revenue rose 15.0% to $602.0 million and adjusted diluted EPS reached $2.11, up from $2.02.

Notably, management reduced its fiscal 2027 guidance. The company now expects revenue of $1.28 billion to $1.29 billion (down from $1.29 billion to $1.315 billion), adjusted diluted EPS of $4.48 to $4.55 (down from $4.55 to $4.65), organic growth roughly flat (down from 1% to 3%), and adjusted free cash flow of at least $265 million. The revision was driven by renewed production variability for Clear Eyes at Pillar5, which began in late September and continued into October.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking consumer healthcare names like PBH, it offers a structured way to surface ideas aligned with specific strategies or market conditions.

Market Reaction and Investor Sentiment

The market's response was decisively negative despite a headline beat. PBH shares fell roughly 16.8% on the day of the report, dropping near the stock's 52-week low and erasing a pre-earnings rally from the prior session. Investors focused less on the acquisition-driven revenue growth and more on the guidance cut, which signaled that the Clear Eyes recovery timeline has slipped again. The contrast between strong adjusted results and weaker organic performance added to the skepticism, as the base business swung from growth in the first quarter to a decline in the second. With the eye-care supply issue now extending into fiscal 2028, sentiment has shifted toward caution on the company's near-term growth trajectory.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Pillar5 can finally stabilize Clear Eyes production. Management has pushed the brand's full recovery into fiscal 2028 and now expects Clear Eyes to generate less than $20 million in revenue this year. Progress at the facility, including site-management changes and any build-up of safety stock, will be a central factor in the next several quarters.

Beyond Clear Eyes, the core portfolio appears resilient. Management noted that organic growth excluding Clear Eyes is running near 2%, supported by brands such as Dramamine, TheraTears, Compound W, and Hydralyte. The successful integration of Breathe Right and LaCorium, both described as on track, remains a key growth driver heading into fiscal 2028.

Financial discipline will also be in focus. Net debt stood at approximately $2.1 billion at quarter-end, and the company has signaled that it intends to use its industry-leading free cash flow to reduce leverage over the remainder of the fiscal year. With adjusted free cash flow guidance now at least $265 million and interest expense projected near $104 million, deleveraging progress will matter as much as top-line growth.

Finally, management reiterated its medium-term targets of roughly 10% annual revenue growth and about 8% annual EPS growth, but those ambitions now hinge on stabilizing eye-care supply and executing on the recent acquisitions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations